Oramed to Present at the 83rd American Diabetes Association Conference

NEW YORK , June 20, 2023 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association’s 83rd Scientific Sessions, taking place between June 23-26,

Oramed Appoints Ben Shapiro to its Board of Directors

NEW YORK , May 1, 2023 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (“Oramed” or the “Company”) ( www.oramed.com ) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023 . The Board determined that Mr.

Oramed Pharmaceuticals Issues Shareholder Update

NEW YORK , Feb. 9, 2023 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials.  In addition, management and the Board of

NEW YORK , Jan. 4, 2023 /PRNewswire/ – Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the

Oramed Letter to Shareholders

Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023 Phase 2 NASH Trial Achieved Primary and Secondary Endpoints Definitive Deal Signed to Commercialize Oral Insulin in South Korea   $160 Million in Cash and Investments (as of September 30, 2022 ) NEW YORK , Dec.

Join our mailing list

Skip to content